China (Mainland)
Assessedsupplier
Ceritinib (LDK378) CAS NO.1032900-25-6
- FOB Price: USD: 10.00-10.00 /Kilogram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
99%(1-99)Kilogram
- Product Details
Keywords
- Ceritinib
- LDK378
- 1032900-25-6
Quick Details
- ProName: Ceritinib (LDK378)
- CasNo: 1032900-25-6
- Molecular Formula: C28H36ClN5O3S
- Appearance: White to off-white powder
- Application: Ceritinib was used in patients with an...
- DeliveryTime: Immediate delivery
- PackAge: 1g/1kg/Al-foiled bag; 25kg/drum
- Port: Any port
- ProductionCapacity: 10 Metric Ton/Day
- Purity: 99%min.
- Storage: Room temperature
- Transportation: By Air,by courier
- LimitNum: 1 Gram
- Moisture Content: Not more than 1.0%
- Impurity: Not more than 2.0%
Superiority
LIDE PHARMACEUTICALS LIMITED is a professional chemicals and APIs leading manufacturer in China. Our core business line covers APIs, Intermediates, Herb extract, etc.
We are specialized in chemical synthesis, process development of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and rare chemicals. We also accept custom synthesis project and contract research services.
R&D strength:
We have well equipped chemicals and instrumental laboratories with modern instruments such as HPLC,GC,IR,UV,NMR,LC-MS etc.
At present, we are selling it with good discount for immediate delivery ! BOOKING TO HASTEN !
Details
(1) Company profile:
Company profile: Lide pharmaceuticals limited
Main products: APIs; Intermediate and other fine chemical products; Piperazine series; Custom Synthesis.
Main Markets: North America; South America; Eastern Europe; Southeast Asia; Africa Oceania; Mid East; Eastern Asia; Western Europe, etc.
(2) Product:
Product Name: Ceritinib (LDK378)
CAS No.: 1032900-25-6
Molecular Formula: C28H36ClN5O3S
Molecular Weight: 558.13514
Appearance: White to off-white powder
Specification: 99%Min.
(3) Application:
Ceritinib was used in patients with anaplastic lymphoma kinase positive (ALK +) metastatic non-small cell lung cancer (NSCLC) after crizotinib intolerance or after treatment of crizotinib with exacerbation.